Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health Inc (NQ: GH )

35.78 +0.26 (+0.73%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Guardant Health Inc

< Previous 1 2 3 4 5 6 Next >
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
From Guardant Health, Inc.
Via Business Wire
Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone
From Guardant Health, Inc.
Via Business Wire
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
From Guardant Health, Inc.
Via Business Wire
Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap
From Guardant Health, Inc.
Via Business Wire
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
From Guardant Health, Inc.
Via Business Wire
Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results
From Guardant Health, Inc.
Via Business Wire
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
From Guardant Health, Inc.
Via Business Wire
Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test
From Guardant Health, Inc.
Via Business Wire
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities
From Guardant Health, Inc.
Via Business Wire
Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Appeal Federal District Court Verdict
From Guardant Health, Inc.
Via Business Wire
Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in Upcoming November Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform
From Guardant Health, Inc.
Via Business Wire
First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer
From Guardant Health, Inc.
Via Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.